echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > IND application for CD47/Her2 double antibody project was accepted by FDA

    IND application for CD47/Her2 double antibody project was accepted by FDA

    • Last Update: 2021-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 28, ImmuneOnco announced that the world's first dual-target antibody-receptor recombinant protein drug targeting human CD47 x Her2 (IMM2902) has been accepted by the US FDA for a new drug clinical research application (IND)


    IMM2902 targets the immunomodulatory targets CD47 and Her2, and inhibits tumor cell growth by accelerating the endocytosis and degradation of Her2; it stimulates the phagocytosis of tumor cells by macrophages by blocking the "don't eat me" signal and activating the "eat me" signal, And present the phagocytosed tumor antigen to T cells, thus exerting a powerful tumor immunotherapy effect


    The product pipeline of ImmuneOnco, sourced from the official website of ImmuneOnco

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.